Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tebanicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 3/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 3/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 4/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 2/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tebanicline SCHEMBL120178 | 1.00 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL29711092 | 1.00 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL677444 | 1.00 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL15663029 | 0.98 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL15663031 | 0.98 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL7407195 | 0.98 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL905233 | 0.89 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL8440116 | 0.89 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL8437569 | 0.88 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL8435785 | 0.88 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 881 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | claimed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | claimed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | claimed |
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| EP-2825208-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | Levicept Ltd. (GB) | 2015-01-21 | — | — | EP | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| WO-2013136078-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2013-09-19 | — | — | WO | claimed |
| EP-1855686-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | Pfizer Limited (GB) | 2007-11-21 | — | — | EP | claimed |
| WO-2006092691-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | claimed |
| US-20050014779-A1 | Compositions and methods for treatment of neurological disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-20 | — | — | US | claimed |
| EP-1434573-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION | Omeros Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| US-20030139387-A1 | Compositions and methods for treatment of neurological disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-24 | — | — | US | claimed |
| WO-2003057140-A2 | COMPOSITION AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF FLORIDA (US) | 2003-07-17 | — | — | WO | claimed |
| US-20020028798-A1 | Irrigation solution and method for inhibition of pain and inflammation | OMEROS MEDICAL SYSTEMS | 2002-03-07 | — | — | US | claimed |
| WO-2000023062-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION | OMEROS MEDICAL SYSTEMS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-6054451-A | THE EFFECTIVENESS OF (R) OR (S) 5-(2-AZETIDINYLMETHOXY)-2-CHLOROPYRIDINE, IS SIGNIFICANTLY POTENTIATED BY ADMINISTERING AN ANALGESIC-POTENTIATING AMOUNT FOR SAID ANALGESIC OF AT LEAST ONE NONTOXIC NMDA RECEPTOR | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-04-25 | — | — | US | claimed |
| WO-1999053922-A1 | ANALGESIC COMPOSITIONS COMPRISING NMDA-ANTAGONISTS AND ABT-594 | ALGOS PHARMACEUTICAL CORPORATION (US) | 1999-10-28 | — | — | WO | claimed |